CLINICAL_TRIALS trial_result · 2021-06-23

Clinical Trial Update: A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC [Phase 3]

Phase 3 trial comparing IBI308 versus Docetaxel in advanced or metastatic non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-06-23